Last reviewed · How we verify

NaMFP — Competitive Intelligence Brief

NaMFP (NaMFP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monocarboxylate transporter inhibitor.

marketed Monocarboxylate transporter inhibitor MCT (monocarboxylate transporter) Small molecule Live · refreshed every 30 min

Target snapshot

NaMFP (NaMFP) — GlaxoSmithKline. NaMFP is a sodium-dependent monocarboxylate transporter inhibitor that reduces cellular uptake of lactate and other monocarboxylates.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NaMFP TARGET NaMFP GlaxoSmithKline marketed Monocarboxylate transporter inhibitor MCT (monocarboxylate transporter)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monocarboxylate transporter inhibitor class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NaMFP — Competitive Intelligence Brief. https://druglandscape.com/ci/namfp. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: